Widely used asthma drug may improve performance of cancer immunotherapies

Montelukast, an already FDA-approved asthma drug sold as Singulair, may improve cancer immunotherapy by blocking CysLTR1 and restoring immune defenses in lab and mouse studies published in Nature Cancer. Researchers also reported that low-dose buprenorphine given after ketamine reduced suicidal ideation by 76% versus 43% for placebo in a 50-patient depression trial. Both findings are early-stage, but they point to potential new uses for existing drugs and could support follow-on clinical trials.

Analysis

This is less a direct equity story than an option on clinical translation speed. The investable signal is that both pathways sit in the “repurposed drug” bucket, which compresses regulatory and CMC risk versus novel assets, so the market is likely to reward platform owners and combo-drug ecosystems faster than single-asset oncology names. If the asthma-drug mechanism replicates in patients, the largest second-order winner is not the branded legacy franchise but the checkpoint-inhibitor universe: even a modest response-rate lift can materially expand duration-adjusted revenue pools in tough solid tumors where current monotherapy response rates are low.

The more important near-term catalyst is not approval, but trial design. If investigators move quickly into biomarker-enriched studies, the earliest readouts could come within 6–12 months and may drive a repricing of adjunct-immunotherapy combinations before any survival data mature. Conversely, if the signal is confined to a narrow myeloid-suppressor phenotype, the commercial impact will be smaller but still meaningful for diagnostics and companion-testing vendors; the negative read-through would be to broad “immunotherapy booster” narratives that currently assume uniform benefit across tumor types.

For the depression work, the key issue is durability versus novelty. Low-dose opioid modulation after ketamine could extend the value of a treatment paradigm that has already shown fast-onset benefit but poor persistence, which would favor clinic chains, infusion operators, and psychedelic-adjacent service models more than drug manufacturers themselves. The main risk is regulatory and reputational: even low-dose opioid positioning could slow adoption, limit prescriber willingness, and cap reimbursement until larger blinded trials exclude dependency concerns and define an optimal maintenance window.

The consensus may be underestimating how much of the upside accrues to “picks and shovels” rather than the repurposed drugs. A successful repurposing thesis tends to compress time-to-market and broaden label scope, but the real valuation re-rate often goes to biomarkers, trial tools, and combination beneficiaries rather than the old molecule with limited patent life. That makes this more attractive as a basket trade around enablement and combo exposure than as a chase into the legacy names themselves.

Key Decisions for Investors

• Long IBB or XBI into the next 3–6 months as a basket expression of faster repurposing/combination-development optionality; risk/reward improves if early biomarker-enriched trial design is announced.
• Pair trade: long EXAS (or another liquid oncology diagnostics name) vs short a broad immuno-oncology basket; if the biomarker thesis proves real, diagnostics can capture the monetization earlier than the drug makers.
• Buy a starter position in large-cap checkpoint inhibitor exposure via MRK or BMY on any 5–10% pullback over the next 1–2 quarters; the upside is incremental combo value, while downside is limited by diversified pipelines.
• For the ketamine theme, prefer service/clinic exposure over pharma beta: long ATAI or a ketamine-adjacent healthcare services basket only on confirmation of larger follow-on data, since the first monetization likely comes through treatment delivery rather than IP.
• Avoid chasing the repurposed legacy molecules until human data are in; use call spreads on XBI instead of outright longs to limit binary trial-risk drawdown.